KHCM
ACHL

Kettle Hill Capital Management’s Achilles Therapeutics ACHL Stock Holding History

Kettle Hill Capital Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-373,558
Closed -$844K – 85
2022
Q3 		$844K Buy
373,558
+130,580
+54% +$370K 0.2% 50
2022
Q2 		$612K Buy
+242,978
New +$600K 0.15% 46

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Kettle Hill Capital Management's ACHL Position: Q4 2022 in Review

Kettle Hill Capital Management sold out of Achilles Therapeutics (ACHL) in Q4 2022, closing a stake of 373,558 shares — an estimated $844K sold.

Kettle Hill Capital Management first reported a position in ACHL in Q2 2022 and held it in 2 quarters. The position peaked at $844K in Q3 2022. 23 funds tracked by Wall St. Rank hold ACHL as of Q4 2022.

  • Kettle Hill Capital Management reported no remaining Achilles Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Kettle Hill Capital Management sold 373,558 Achilles Therapeutics shares in Q4 2022, an estimated $844K.
  • Kettle Hill Capital Management first reported a position in Achilles Therapeutics in Q2 2022 and held it in 2 quarters.
  • Kettle Hill Capital Management's Achilles Therapeutics position peaked at $844K in Q3 2022.
  • 23 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2022.

Based on Kettle Hill Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.